By utilizing keratinocytes representing different stages in the multistep process of skin carcinogenesis, we report that vemurafenib-associated MEK-ERK hyperactivation accelerates epidermal differentiation in different keratinocytes correlating with the vemurafenib-dependent adverse event of hyperkeratosis. This evidence concerns the gene MAP2K7 and Hyperkeratosis.